N-n-pentyl-N'-cyano-O-phenylisourea | 899790-38-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-n-pentyl-N'-cyano-O-phenylisourea
• 英文别名: phenyl N-cyano-N'-pentylcarbamimidate
• CAS: 899790-38-6
• 化学式: C₁₃H₁₇N₃O
• 分子量: 231.297
• InChiKey: QCVTWIZXUXIKCA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  57.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-n-pentyl-N'-cyano-O-phenylisourea 、 2-(3,5-dimethylphenylamino)-5-nitrobenzenesulfonamide 在 sodium hydroxide 作用下， 以 丙酮 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.17h， 生成 N-n-pentyl-N'-[2-(3,5-dimethylphenylamino)-5-nitrobenzenesulfonyl]-N''-cyanoguanidine
  参考文献：
  名称：

  Synthesis and Pharmacological Evaluation of Novel Nitrobenzenic Thromboxane Modulators as Antiplatelet Agents Acting on Both the Alpha and Beta Isoforms of the Human Thromboxane Receptor

  摘要：

  Thromboxane A(2) ( TXA(2)) is an arachidonic acid metabolite involved in pathologies such as stroke, myocardial infarction, and atherosclerosis. Consequently, the design of TXA2 receptor ( TP) antagonists remains of great interest in cardiovascular medicine. The actions of TXA2 are mediated by its specific G-protein coupled receptor of which two alternative spliced isoforms, TP alpha and TP beta, have been described in humans. In this study, we report the synthesis of a series of original N-alkyl-N'-[2-( cycloalkyl, alkylaryl)-5-nitrobenzenesulfonyl] urea and N-alkyl-N'-[ 2-( alkylaryl)-5-nitrobenzenesulfonyl]-N"-cyanoguanidines and outline their pharmacological evaluation using the individual TP alpha and TP beta isoforms. Among compounds analyzed, several of them exhibited greater affinity and/or functional activity for either TP alpha or TP beta. The most promising molecules were also found to be antiplatelet agents. From the present results, structural features involved in isoform selectivity can be proposed, and thereby several lead compounds have been identified for the further development of selective TP isoform antagonists.

  DOI：

  10.1021/jm060108a
• 作为产物：
  描述：

  N-氰基羰亚胺二苯基酯 、 1-氨基戊烷 以 异丙醇 为溶剂， 反应 0.17h， 生成 N-n-pentyl-N'-cyano-O-phenylisourea
  参考文献：
  名称：

  Synthesis and Pharmacological Evaluation of Novel Nitrobenzenic Thromboxane Modulators as Antiplatelet Agents Acting on Both the Alpha and Beta Isoforms of the Human Thromboxane Receptor

  摘要：

  Thromboxane A(2) ( TXA(2)) is an arachidonic acid metabolite involved in pathologies such as stroke, myocardial infarction, and atherosclerosis. Consequently, the design of TXA2 receptor ( TP) antagonists remains of great interest in cardiovascular medicine. The actions of TXA2 are mediated by its specific G-protein coupled receptor of which two alternative spliced isoforms, TP alpha and TP beta, have been described in humans. In this study, we report the synthesis of a series of original N-alkyl-N'-[2-( cycloalkyl, alkylaryl)-5-nitrobenzenesulfonyl] urea and N-alkyl-N'-[ 2-( alkylaryl)-5-nitrobenzenesulfonyl]-N"-cyanoguanidines and outline their pharmacological evaluation using the individual TP alpha and TP beta isoforms. Among compounds analyzed, several of them exhibited greater affinity and/or functional activity for either TP alpha or TP beta. The most promising molecules were also found to be antiplatelet agents. From the present results, structural features involved in isoform selectivity can be proposed, and thereby several lead compounds have been identified for the further development of selective TP isoform antagonists.

  DOI：

  10.1021/jm060108a

文献信息

• [EN] CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS<br/>[FR] CYANOGUANIDINES ET LEUR UTILISATION COMME AGENTS ANTIVIRAUX
  申请人：ABBVIE INC

  公开号：WO2014005129A1

  公开（公告）日：2014-01-03

  This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

  这份披露涉及：(a) 抑制RSV感染和/或复制的化合物及其盐，等等；(b) 用于制备这些化合物和盐的中间体；(c) 包含这些化合物和盐的组合物；(d) 制备这些中间体、化合物、盐和组合物的方法；(e) 使用这些化合物、盐和组合物的方法；以及(f) 包含这些化合物、盐和组合物的试剂盒。
• Diaminotriazole compounds useful as protein kinase inhibitors
  申请人：Salituro Francesco

  公开号：US20060063756A1

  公开（公告）日：2006-03-23

  The present invention relates to inhibitors of protein kinases, particularly to inhibitors of JAK2 and JAK3. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods of using the compositions in the treatment of various disorders.

  本发明涉及蛋白激酶的抑制剂，特别是JAK2和JAK3的抑制剂。该发明还提供包括该发明化合物的药物组合物，制备该化合物的方法以及在治疗各种疾病中使用该组合物的方法。
• CYANOGUANIDINES AND USES THEREOF
  申请人：Abbvie Inc.

  公开号：US20150322045A1

  公开（公告）日：2015-11-12

  This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

  本披露涉及：(a)化合物及其盐，其中包括抑制RSV感染和/或复制的化合物和盐; (b)用于制备这种化合物和盐的中间体; (c)包含这种化合物和盐的组合物; (d)制备这种中间体，化合物，盐和组合物的方法; (e)使用这种化合物，盐和组合物的方法; 和 (f)包含这种化合物，盐和组合物的工具包。
• Substituted cyanoguanidines as oral anti-virals
  申请人：Abbvie Inc

  公开号：US10112911B2

  公开（公告）日：2018-10-30

  This disclosure relates to: (a) compounds and salts of formula (I), formula (II), formula (III), and formula (IV), that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

  本公开涉及(a) 式(I)、式(II)、式(III)和式(IV)化合物和盐，除其他外，可抑制 RSV 感染和/或复制；(b) 用于制备此类化合物和盐的中间体；(c) 包含此类化合物和盐的组合物；(d) 制备此类中间体、化合物、盐和组合物的方法；(e) 此类化合物、盐和组合物的使用方法；以及 (f) 包含此类化合物、盐和组合物的试剂盒。
• DIAMINOTRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1791830A1

  公开（公告）日：2007-06-06